Discovering breakthroughs in fibrosis and neurodegeneration

Our Pipeline

Blade Therapeutics is advancing a differentiated pipeline of oral, small-molecule therapies that include a non-competitive autotaxin inhibitor and multiple inhibitors of dimeric calpains for the potential treatment of lung, liver and cardiac fibrosis or neurodegenerative diseases. Since the company’s founding in 2015, Blade has used a combination of in-house drug research and selective in-licensing to build a risk-diversified pipeline.

Our focused approach offers the potential to produce disease-modifying, life-saving therapies.

1 Autotaxin Inhibitor
2 Calpain Inhibitor